PMID- 31889588 OWN - NLM STAT- MEDLINE DCOM- 20201215 LR - 20201215 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 216 IP - 2 DP - 2020 Feb TI - The clinical significance and potential molecular mechanism of integrin subunit beta 4 in laryngeal squamous cell carcinoma. PG - 152785 LID - S0344-0338(19)32173-9 [pii] LID - 10.1016/j.prp.2019.152785 [doi] AB - The relationship between integrin beta 4 (ITGB4) expression and laryngeal squamous cell carcinoma (LSCC) remains unclarified. The object of the present study was to explore the clinical significance and potential molecular mechanism of ITGB4 in LSCC. The protein level of ITGB4 was significantly higher in 46 LSCC patients than in 26 non-LSCC tissues detected by in-house immunohistochemistry. Consistently, ITGB4 mRNA level was also greatly upregulated based on microarray and RNA-seq data (standard mean difference, SMD = 1.62, 95 % CI: 1.23-2.00). And the area under curves (AUC) of summary receiver operator characteristic (SROC) was 0.87 (95 % CI: 0.84-0.90) based on 172 cases of LSCC and 59 cases of non-cancerous controls. Ninety genes were intersected by the ITGB4 related genes and LSCC differential expressed genes (DEGs) from all available microarray and RNA-seq datasets. Based on Gene Ontology (GO) analysis, the top terms of biological process (BP), cellular component (CC) and molecular function (MF) for the 90 ITGB4 related DEGs were extracellular matrix organization, basement membrane and extracellular matrix structural constituent, respectively. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that ITGB4 related DEGs mainly participated in the pathways of ECM-receptor interaction, Focal adhesion and Small cell lung cancer. Moreover, the Protein-Protein Interaction (PPI) network indicated that ITGA3, ITGA5, ITGB4, MET, LAMA3, and COL4A1 might be the core genes of LSCC development related to ITGB4. In conclusion, high ITGB4 expression may lead to the occurrence and development of LSCC via various signaling pathways. CI - Copyright (c) 2019 Elsevier GmbH. All rights reserved. FAU - Zhong, Feng AU - Zhong F AD - Department of Pathology, Hengxian People's Hospital, 141 Jiaoyu Road, Hengxian County of Nanning 530300, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Lu, Hui-Ping AU - Lu HP AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Chen, Gang AU - Chen G AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Dang, Yi-Wu AU - Dang YW AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Li, Guo-Sheng AU - Li GS AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Chen, Xiao-Yi AU - Chen XY AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Qin, Yong-Ying AU - Qin YY AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Yao, Yu-Xuan AU - Yao YX AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Zhang, Xiao-Guohui AU - Zhang XG AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Liang, Yao AU - Liang Y AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Li, Ming-Xuan AU - Li MX AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Mo, Miao AU - Mo M AD - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Zhang, Kai-Lang AU - Zhang KL AD - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Ding, Hua AU - Ding H AD - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. FAU - Huang, Zhi-Guang AU - Huang ZG AD - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. Electronic address: huangzhiguang@gxmu.edu.cn. FAU - Wei, Zhu-Xin AU - Wei ZX AD - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, People's Republic of China. Electronic address: weizhuxin@stu.gxmu.edu.cn. LA - eng PT - Journal Article DEP - 20191216 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (ITGB4 protein, human) RN - 0 (Integrin beta4) SB - IM MH - Carcinoma, Squamous Cell/*genetics/metabolism/pathology MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Gene Ontology MH - Humans MH - Immunohistochemistry MH - Integrin beta4/genetics/*metabolism MH - Laryngeal Neoplasms/*genetics/metabolism/pathology MH - Larynx/pathology MH - Male MH - Microarray Analysis MH - Middle Aged MH - Protein Interaction Mapping MH - Sequence Analysis, RNA MH - *Signal Transduction OTO - NOTNLM OT - Immunohistochemistry OT - Integrin subunit beta 4 OT - Larynx OT - Microarray OT - RNA-sequencing OT - Squamous cell carcinoma COIS- Declaration of Competing Interest None. EDAT- 2020/01/01 06:00 MHDA- 2020/12/16 06:00 CRDT- 2020/01/01 06:00 PHST- 2019/10/07 00:00 [received] PHST- 2019/11/21 00:00 [revised] PHST- 2019/12/10 00:00 [accepted] PHST- 2020/01/01 06:00 [pubmed] PHST- 2020/12/16 06:00 [medline] PHST- 2020/01/01 06:00 [entrez] AID - S0344-0338(19)32173-9 [pii] AID - 10.1016/j.prp.2019.152785 [doi] PST - ppublish SO - Pathol Res Pract. 2020 Feb;216(2):152785. doi: 10.1016/j.prp.2019.152785. Epub 2019 Dec 16.